ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration
Virtual update meeting – Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies
ACCELERATE, in collaboration with the EMA, and with participation of the FDA, is holding a virtual update meeting on anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies on 13 and 14 January 2021 over two half days.
In 2017 the first Paediatric Strategy Forum on ALK inhibition was held and as it is now three years since this meeting, four more Paediatric Strategy Forums have been held and the landscape of ALK inhibitors has evolved, it was believed that it would be beneficial now to hold an update meeting.
The goal is to share information between all stakeholders, to evaluate science, to inform paediatric drug development strategies and subsequent decisionsThe update meeting aims to:
- Review ALK biology in neuroblastoma, inflammatory myofibroblastic tumour, anaplastic large cell lymphoma and central nervous system tumours
- Identify the current unmet needs in children
- Identify lessons learnt in last three years
- Plan how do we evaluate second/third generation products (if unmet needs are) fulfilled?
(This will be relevant to ALK inhibitors and other products.)
The output of the meeting will be a published summary and manuscript.